Last reviewed · How we verify
Onbrez
At a glance
| Generic name | Onbrez |
|---|---|
| Also known as | LABA |
| Sponsor | Fundacio Privada Mon Clinic Barcelona |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma (PHASE3)
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (PHASE3)
- Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma (PHASE3)
- A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (PHASE2)
- ANTES B+ Clinical Trial (PHASE4)
- A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®
- Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD (PHASE1, PHASE2)
- Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Onbrez CI brief — competitive landscape report
- Onbrez updates RSS · CI watch RSS
- Fundacio Privada Mon Clinic Barcelona portfolio CI